Results 71 to 80 of about 272,115 (210)

Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy

open access: yesScientific Reports, 2021
Polypoidal choroidal vasculopathy (PCV) is a vision-threatening disease common in Asian populations. However, the optimal treatment for PCV remains under debate. We searched the databases with optimal searching strategy.
Sheng-Chu Chi, Yi-No Kang, Yi-Ming Huang
doaj   +1 more source

RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition [PDF]

open access: yes, 2019
BRCA1/2 mutations play a predictive role in ovarian cancer risk evaluation. Moreover , patients are today being tested for BRCA1/2 mutations to select a tailored therapy too , because they could benefit from a treatment with PARP inhibitors (PARPi ...
Panici, Pierluigi Benedetti   +2 more
core   +1 more source

VEGF(164)-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization [PDF]

open access: yes, 2003
Hypoxia-induced VEGF governs both physiological retinal vascular development and pathological retinal neovascularization. In the current paper, the mechanisms of physiological and pathological neovascularization are compared and contrasted.
Adamis, AP   +14 more
core   +1 more source

Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular Degeneration. [PDF]

open access: yes, 2019
Age-related macular degeneration (AMD) - the leading cause of vision loss in the elderly - share many risks factors as atherosclerosis, which exhibits loss of vascular compliance resulting from aging and oxidative stress.
Agrawal, Rupesh   +8 more
core   +2 more sources

Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy [PDF]

open access: yes, 2017
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease; the identification of novel targets and development of effective treatment strategies are urgently needed to improve patient outcomes.
Olson, Michael F.   +4 more
core   +1 more source

Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis

open access: yesBMC Ophthalmology
Background Topical non-steroidal anti-inflammatory drugs have the potential to reduce treatment burden and improve outcomes of anti-VEGF therapy for a number of retinal disorders, including neovascular age-related macular degeneration, diabetic macular ...
Alexei N. Kulikov   +3 more
doaj   +1 more source

The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy

open access: yesJournal of Advanced Research
Introduction: The efficacy of anti-vascular endothelial growth factor (VEGF) therapy is limited. However, the key factors involved in limiting the efficacy of anti-VEGF therapy and the underlying mechanisms remain unclear.
Yumin Qiu   +8 more
doaj   +1 more source

Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future [PDF]

open access: yes, 2019
Ocular diseases cause visual impairment and blindness, imposing a devastating impact on quality of life and a substantial societal economic burden. Many such diseases lack universally effective pharmacotherapies.
Corson, Timothy W., Park, Bomina
core   +1 more source

Cost effectiveness of treatments for wet age-related macular degeneration [PDF]

open access: yes, 2011
Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven   +4 more
core   +1 more source

Is There a Relationship Between Use of Anti-Vascular Endothelial Growth Factor Agents and Atrophic Changes in Age-Related Macular Degeneration Patients?

open access: yesTürk Oftalmoloji Dergisi, 2018
Choroidal neovascularization due to age-related macular degeneration (AMD) is currently treated successfully with anti-vascular endothelial growth factor (VEGF) intravitreal agents.
Süleyman Kaynak   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy